Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy

27. juli 2026 oppdatert av: Riphah International University

Comparative Effects of Acapella and Flutter Devices on Secretion Clearance, Dyspnea, Arterial Blood Gases, and Lung Function Test in Post-Lobectomy Patients

Lobectomy patients frequently experience postoperative respiratory complications such as secretion retention, dyspnea, impaired gas exchange, and reduced lung function, which can delay recovery. Oscillatory Positive Expiratory Pressure (OPEP) devices such as Acapella and Flutter are commonly used to improve airway clearance and pulmonary function. This study aims to compare the effects of Acapella and Flutter devices on secretion clearance, dyspnea, arterial blood gases, and lung function in post-lobectomy patients.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Lobectomy is a common surgical procedure performed for the treatment of various pulmonary conditions, particularly lung cancer. Although effective, the procedure is often associated with postoperative respiratory complications including mucus retention, reduced lung volumes, impaired ventilation, and difficulty breathing. These complications can prolong hospital stay, increase the risk of infection, and negatively affect functional recovery.

Respiratory physiotherapy plays an important role in preventing and managing these complications. Oscillatory Positive Expiratory Pressure (OPEP) devices are widely used to facilitate airway clearance by generating positive expiratory pressure and oscillations during exhalation. These mechanisms help mobilize retained secretions, improve ventilation, enhance lung expansion, and support overall pulmonary recovery.

Acapella and Flutter are two commonly used OPEP devices. Both have demonstrated beneficial effects on mucus clearance, pulmonary function, oxygenation, and symptom management in patients with respiratory disorders and postoperative conditions. Previous studies have reported improvements in respiratory parameters and functional outcomes following the use of these devices as part of pulmonary rehabilitation programs.

Despite the growing use of OPEP devices in clinical practice, evidence directly comparing Acapella and Flutter in patients recovering from lobectomy remains limited. Most available studies have focused on chronic respiratory diseases or evaluated these devices independently rather than comparing their effectiveness in a postoperative population. Furthermore, limited information is available regarding their relative effects on secretion clearance, dyspnea, arterial blood gases, and lung function after lobectomy. Therefore, this study is designed to address this gap and provide evidence regarding the comparative effectiveness of Acapella and Flutter devices in postoperative pulmonary rehabilitation.

Studietype

Intervensjonell

Registrering (Antatt)

28

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 55000
        • Rekruttering
        • Riphah International University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Humera Ayub, MSCPPT
        • Hovedetterforsker:
          • Tanzeela Nazir, MSCPPT

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Patients aged 35 to 54 years
  • Both male and female patients
  • Patients who have undergone lobectomy surgery
  • Hemodynamically stable patients
  • Patients with adequate respiratory function (able to maintain oxygenation)
  • Patients 48 hours post-surgery
  • Patients who provide written informed consent to participate in the study

Exclusion Criteria:

  • Hemodynamically unstable patients
  • Patients within less than 48 hours post-surgery
  • Presence of pneumothorax or air leak complications
  • Patients with recent major trauma or additional surgery
  • Patients with unstable cardiac conditions
  • Patients with massive hemoptysis
  • Patients unable to cooperate or perform breathing exercises with devices
  • Any contraindication to airway clearance techniques as judged by the clinician

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Acapella Device Group
Participants in this arm will receive airway clearance therapy using the Acapella device. The device combines both positive expiratory pressure (PEP) and airway vibration to enhance mobilization of bronchial secretions. Patients will be trained to perform standardized breathing techniques using the device. The intervention will be administered twice daily for 7 days, under supervision during hospital stay or as per protocol guidelines. Standard post-lobectomy care will be continued alongside the intervention.
Enhet: Acapella Device Therapy (Experimental Arm 1):
1. Acapella Device Therapy (Experimental Arm 1): Participants will use the Acapella device, which provides a combination of oscillating positive expiratory pressure (OPEP) and airway vibration to facilitate mucus clearance. Patients will be trained in proper technique and will perform the intervention twice daily for 7 days. Each session will follow a standardized protocol to ensure consistency in breathing pattern and device usage.
Aktiv komparator: Flutter Device Group
Participants in this arm will receive airway clearance therapy using the Flutter device, which generates oscillatory positive expiratory pressure to loosen and mobilize airway secretions. Patients will be instructed in proper usage technique to ensure effective airflow oscillation during exhalation. The intervention will be performed twice daily for 7 days, following a standardized protocol similar to the Acapella group. Routine post-operative care will be provided in addition to the intervention.
Enhet: Flutter Device Therapy (Experimental Arm 2):

Flutter Device Therapy (Experimental Arm 2):

Participants will use the Flutter device, which generates oscillating positive expiratory pressure during exhalation to mobilize bronchial secretions. Patients will be instructed in correct positioning and breathing technique. The intervention will also be administered twice daily for 7 days using a standardized protocol.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Dyspnea Score
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Change in perceived breathlessness measured using the Modified Borg Dyspnea Scale (0-10, higher scores indicate greater dyspnea).
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Forced Expiratory Volume in One Second (FEV₁)
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Forced Expiratory Volume in one second (FEV₁) measured using spirometry and reported in liters (L).
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Forced Vital Capacity (FVC)
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Forced Vital Capacity (FVC) measured using spirometry and reported in liters (L).
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
FEV₁/FVC Ratio
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV₁/FVC) measured using spirometry and reported as a percentage (%).
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sputum Volume
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Volume of sputum expectorated over a 24-hour period, reported in milliliters (mL), to assess airway secretion clearance.
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Partial Pressure of Oxygen (PaO₂)
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Arterial partial pressure of oxygen (PaO₂) measured using arterial blood gas analysis and reported in millimeters of mercury (mmHg).
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Partial Pressure of Carbon Dioxide (PaCO₂)
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Arterial partial pressure of carbon dioxide (PaCO₂) measured using arterial blood gas analysis and reported in millimeters of mercury (mmHg).
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Arterial Blood pH
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Arterial blood pH measured using arterial blood gas analysis.
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Bicarbonate Concentration (HCO₃-)
Tidsramme: Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5
Arterial bicarbonate (HCO₃-) concentration measured using arterial blood gas analysis and reported in millimoles per liter (mmol/L).
Postoperative Day 1, Postoperative Day 3, and Postoperative Day 5

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Presence of Postoperative Atelectasis on Chest X-ray
Tidsramme: Postoperative Day 1 and Postoperative Day 5
Number of participants with radiographic evidence of postoperative atelectasis as assessed by standard chest radiography.
Postoperative Day 1 and Postoperative Day 5
Presence of Pleural Effusion on Chest X-ray
Tidsramme: Postoperative Day 1 and Postoperative Day 5
Number of participants with radiographic evidence of pleural effusion as assessed by standard chest radiography.
Postoperative Day 1 and Postoperative Day 5

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Riphah International University

Etterforskere

  • Hovedetterforsker: Tanzeela Nazir, MSCPPT, Riphah International University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. juni 2026

Primær fullføring (Antatt)

15. november 2026

Studiet fullført (Antatt)

15. desember 2026

Datoer for studieregistrering

Først innsendt

21. juli 2026

Først innsendt som oppfylte QC-kriteriene

27. juli 2026

Først lagt ut (Faktiske)

30. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • REC/RCR & AHS/25/0316

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual Participant Data (IPD) from this study will not be shared publicly due to ethical and privacy considerations, including the risk of identifying post-lobectomy patients from a small sample size. Additionally, the data may contain sensitive clinical information such as arterial blood gas results and postoperative respiratory status, which require strict confidentiality.

However, de-identified aggregate data may be available upon reasonable request from the corresponding investigator, subject to institutional approval and ethical committee permissions.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere